Gilead Sciences’ (GILD) CEO Daniel O’Day is MIA, and so is the biotech’s promised return to growth.

O’Day, the longtime Roche executive, was named Gilead’s new CEO in December, but here we are two months later and he’s not yet shown up on the job. Commitments with Roche won’t allow O’Day to take over the Gilead executive suite until March 1, a Gilead spokesperson said.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy